5-氨基水杨酸对柳氮磺胺吡啶不耐受或过敏的炎性肠病患者的价值。
The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
作者信息
Donald I P, Wilkinson S P
出版信息
Postgrad Med J. 1985 Dec;61(722):1047-8. doi: 10.1136/pgmj.61.722.1047.
Abstract
The use of sulphasalazine in inflammatory bowel disease is often limited by intolerance or allergy. In previous studies 5-aminosalicylic acid (5ASA), the active ingredient of sulphasalazine, coated with an acrylic resin, has been shown to be as effective as sulphasalazine in maintaining remission. In this study coated 5ASA was given to 37 patients intolerant or allergic to sulphasalazine. Thirty-three patients have tolerated 5ASA satisfactorily, and most experienced improved control of their disease. Four patients reported similar side effects with sulphasalazine and 5ASA.
摘要
柳氮磺胺吡啶在炎症性肠病中的应用常因不耐受或过敏而受到限制。在以往的研究中，已表明柳氮磺胺吡啶的活性成分5-氨基水杨酸（5ASA）包以丙烯酸树脂后，在维持缓解方面与柳氮磺胺吡啶同样有效。在本研究中，给37例对柳氮磺胺吡啶不耐受或过敏的患者服用包衣5ASA。33例患者对5ASA耐受良好，且大多数患者病情得到了更好的控制。4例患者报告柳氮磺胺吡啶和5ASA有相似的副作用。
相似文献
1
The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.5-氨基水杨酸对柳氮磺胺吡啶不耐受或过敏的炎性肠病患者的价值。
Postgrad Med J. 1985 Dec;61(722):1047-8. doi: 10.1136/pgmj.61.722.1047.
2
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.包衣美沙拉嗪（5-氨基水杨酸）与柳氮磺胺吡啶治疗活动期溃疡性结肠炎的随机对照试验
BMJ. 1989 Jan 14;298(6666):82-6. doi: 10.1136/bmj.298.6666.82.
3
Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?艾莎可在维持克罗恩病和溃疡性结肠炎缓解方面与柳氮磺胺吡啶一样有效吗？
Postgrad Med J. 1992 Mar;68(797):189-91. doi: 10.1136/pgmj.68.797.189.
4
Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.柳氮磺胺吡啶与丙烯酸包衣5-氨基水杨酸在正常受试者和结肠炎患者中的吸收与代谢比较。
Br J Clin Pharmacol. 1984 Apr;17(4):474-6. doi: 10.1111/j.1365-2125.1984.tb02375.x.
5
Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
Scand J Gastroenterol. 1987 Apr;22(3):332-6. doi: 10.3109/00365528709078600.
6
Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.美沙拉嗪（艾迪莎）肠溶包衣片治疗炎症性肠病的经验：一项开放性研究
J Clin Gastroenterol. 1993 Oct;17(3):213-8. doi: 10.1097/00004836-199310000-00009.
7
Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides.炎症性肠病患者以及既往对柳氮磺胺吡啶或磺胺类药物不耐受或过敏患者的美沙拉嗪耐受性。
Scand J Gastroenterol. 1987 Sep;22(7):798-802. doi: 10.3109/00365528708991917.
8
9
Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects.柳氮磺胺吡啶和5-氨基水杨酸用于溃疡性结肠炎的长期治疗：耐受性和副作用报告
Dig Liver Dis. 2001 Oct;33(7):563-9. doi: 10.1016/s1590-8658(01)80108-0.
10
Mesalazine in childhood inflammatory bowel disease.
Aliment Pharmacol Ther. 1989 Dec;3(6):597-603. doi: 10.1111/j.1365-2036.1989.tb00253.x.
引用本文的文献
1
Characteristics of Mucosa-Associated Microbiota in Ulcerative Colitis Patients with 5-Aminosalicylic Acid Intolerance.对5-氨基水杨酸不耐受的溃疡性结肠炎患者黏膜相关微生物群的特征
Biomedicines. 2024 Sep 19;12(9):2125. doi: 10.3390/biomedicines12092125.
2
Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.口服缓释美沙拉嗪：其在溃疡性结肠炎和克罗恩病中的应用综述
Drugs. 1999 Mar;57(3):383-408. doi: 10.2165/00003495-199957030-00013.
3
Pharmacology and pharmacokinetics of 5-aminosalicylic acid.5-氨基水杨酸的药理学与药代动力学
Dig Dis Sci. 1987 Dec;32(12 Suppl):46S-50S. doi: 10.1007/BF01312463.
4
Medical treatment of ulcerative colitis: scoring the advances.溃疡性结肠炎的医学治疗：评估进展
Gut. 1988 Oct;29(10):1298-303. doi: 10.1136/gut.29.10.1298.
5
Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.延迟释放型5-氨基水杨酸（美沙拉嗪）与柳氮磺胺吡啶治疗轻至中度溃疡性结肠炎复发的比较。
Gut. 1988 May;29(5):669-74. doi: 10.1136/gut.29.5.669.
6
Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.美沙拉嗪。对其药效学和药代动力学特性以及在慢性炎症性肠病中的治疗潜力的综述。
Drugs. 1989 Oct;38(4):500-23. doi: 10.2165/00003495-198938040-00003.
7
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.包衣美沙拉嗪（5-氨基水杨酸）与柳氮磺胺吡啶治疗活动期溃疡性结肠炎的随机对照试验
BMJ. 1989 Jan 14;298(6666):82-6. doi: 10.1136/bmj.298.6666.82.
8
Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?艾莎可在维持克罗恩病和溃疡性结肠炎缓解方面与柳氮磺胺吡啶一样有效吗？
Postgrad Med J. 1992 Mar;68(797):189-91. doi: 10.1136/pgmj.68.797.189.
本文引用的文献
1
An oral preparation to release drugs in the human colon.一种在人体结肠释放药物的口服制剂。
Br J Clin Pharmacol. 1982 Sep;14(3):405-8. doi: 10.1111/j.1365-2125.1982.tb01999.x.
2
Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis.溃疡性结肠炎患者使用5-氨基水杨酸治疗后腹泻和疼痛加剧。
Lancet. 1984 Apr 21;1(8382):917-8. doi: 10.1016/s0140-6736(84)91386-2.
3
Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.口服高剂量5-氨基水杨酸维持溃疡性结肠炎缓解
Br Med J (Clin Res Ed). 1983 Jul 2;287(6384):23-4. doi: 10.1136/bmj.287.6384.23.
4
Congenital cytomegalovirus infection.先天性巨细胞病毒感染
Lancet. 1983 Apr 9;1(8328):801-2.
5
Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.柳氮磺胺吡啶用于溃疡性结肠炎维持治疗的最佳剂量。
Gut. 1980 Mar;21(3):232-40. doi: 10.1136/gut.21.3.232.
6
A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).柳氮磺胺吡啶（水杨酸偶氮磺胺吡啶）对溃疡性结肠炎进行长期维持治疗的对照治疗试验。
Gut. 1973 Dec;14(12):923-6. doi: 10.1136/gut.14.12.923.
7
An experiment to determine the active therapeutic moiety of sulphasalazine.一项确定柳氮磺胺吡啶活性治疗部分的实验。
Lancet. 1977 Oct 29;2(8044):892-5. doi: 10.1016/s0140-6736(77)90831-5.
8
National Cooperative Crohn's Disease Study: results of drug treatment.全国克罗恩病合作研究：药物治疗结果
Gastroenterology. 1979 Oct;77(4 Pt 2):847-69.
Zotero 插件